Back to mobile site
Get it on Google Play

FDA grants priority review to Genentech's Gazyva for kidney disease

July 15, 2026 1:01 AM EDT Send to a Friend
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said the U.S. Food and Drug Administration has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login